Rakovina Therapeutics

kt-2000AI

Deep Docking™ : AI Driven Discovery of Best-in-Class Cancer Therapies

Beyond the success of PARP inhibitors, the field of DNA-damage response inhibition has unveiled a wealth of promising targets for cancer treatment. The emergence of new targets provides a rich landscape of potential strategies poised to revolutionize the treatment of cancer.

Rakovina Therapeutics is employing the proprietary Deep Docking AI Platform to rapidly screen billions of potential drug candidates against PARP (kt-2000AI) and other novel DDR targets to generate best-in-class drug candidates that can be advanced to human trials or developed in collaboration with pharmaceutical partners.